Single Dose Study Of GW856553 On A Protein That Is An Indicator For Rheumatoid Arthritis (RA)

GlaxoSmithKline51 enrolled

Overview

This study is designed to compare a range of doses of GW856553 versus placebo on the biomarkers associated with rheumatoid arthritis

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Arthritis, Rheumatoid

Interventions

GW856553DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: * Must have a diagnosis of RA according to the revised 1987 criteria of the American College of Rheumatology. * Must have 3 or more swollen or 3 or more tender/painful joints at screening. * Must be on stable weekly methotrexate (2.5mg-25mg) for at least eight weeks prior to screening. Exclusion criteria: * Must not be morbidly obese.

Locations (17)

GSK Investigational Site

Plovdiv, Bulgaria

GSK Investigational Site

Sofia, Bulgaria

GSK Investigational Site

Outcomes

Primary Outcomes

C-reactive protein (CRP) levels 72 hours post-dose.

Time frame: 72 hours post-dose.

Secondary Outcomes

C-reactive protein (CRP) levels 24 and 48 hours post-dose

Time frame: 24 and 48 hours post-dose

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.